Deals, Development and Manufacturing

Kala’s acquisition of Combangio expands its clinical-stage biologic pipeline.

Under the expanded agreement with Agios, Centogene will provide global clinical trial support for thalassemia and sickle cell diseases.

AbbVie will pay REGENXBIO up to $1.75 billion for the rights to develop and commercialize its treatment of various eye conditions.

The agreement will allow Birmingham Biotech to commercialize the University of Birmingham’s antiviral COVID-19 nasal spray.

Element’s acquisition of JMI Laboratories will increase their North American service offerings.

Lonza is expanding its exosomes development and manufacturing capabilities with the acquisition of a service unit from Exosomics and a manufacturing facility from Codiak BioSciences.

Aceragen’s acquisition of Arrevus adds key treatment candidates to its rare disease pipeline.

Takeda’s acquisition of GammaDelta Therapeutics expands their immuno-oncology and innate immune cell therapy portfolio.

Following the acquisition, Avantor will have access to Masterflex’s various bioproduction operations.

The research collaboration between Sartorius and Matica Biotechnology will aim to optimize PAT technologies, automation software, and single-use platforms for large-scale viral vector production.

The $691 million deal will see Vertex use Mammoth’s systems to discover and develop in-vivo gene-editing therapies.

Ajinomoto and its subsidiary company, Ajinomoto Genexine, have partnered with Insilico Biotechnology to accelerate and improve process development and production of biologics using digital twin technology.

Merck’s agreement with the Medicines Patent Pool (MPP) aims to facilitate affordable global access for molnupiravir.

Crystec and Biosidus have joined forces to enhance the delivery and performance of biotherapeutics.

The collaboration between Intellia and SparingVision will work to develop genomic medicines for ocular diseases.

This acquisition grants Bionano access to BioDiscovery’s clinical software solution for variant analysis.

Pharmalex has launched the Biopharma Excellence brand, a new service line that combines the expertise of PharmaLex, ERA Consulting, and Biopharma Excellence.

SGS is investing in a new E&L lab in Navi Mumbai, India, that will provide testing services.

AION Labs will be a first-of-its-kind AI/pharma and computational biology innovation lab aimed at spearheading the adoption of AI technologies and computational science.

Element’s acquisition of Nanosyn is the latest in a series of moves made to strengthen the company’s North American presence.

Pacira’s acquisition grants them access to Flexion’s pain management portfolio.

Supernus will acquire Adamas’ Parkinson's disease treatment portfolio through a $400 million acquisition.

Pfizer may pay up to $630 million for access to Voyager’s novel AAV capsids in transgene research.

The collaboration between Sunovion, Sumitomo Dainippon, and Otsuka will focus on four compounds designed to treat neuropsychiatric health conditions.

Certara’s acquisition of Pinnacle 21 grants them access to their compliance validation software.